Advances in the Multidisciplinary Management of Hepatocellular Carcinoma (HCC): Strategies for Incorporating Emerging Immunotherapy Treatment Options
| Overview / Abstract: |
Expert faculty, Richard Finn, MD, discusses treatment options and strategies in a case-based approach for two patients who have failed conventional therapies and may be candidates for immunotherapy. The activity features an online virtual patient platform that affords clinicians an opportunity to absorb relevant clinical and evidence-based information. The purpose of the activity is to inform clinicians on integrating immunotherapy into treatment options of advanced hepatocellular carcinoma patients through a case-based discussion. |
|
Expiration |
Mar 30, 2019 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
.50 |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Richard S. Finn, MD |
|
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from Merck & Co., Inc. |
|
Keywords / Search Terms |
ACHL HCC, hepatocellular, hepatocellular carcinoma, complex, tumor, chronic, liver, hepatitis, metastatic, cirrhosis, checkpoint inhibitor, checkpoint, inhibitor, first line, second line, novel, oncology, oncologist, case, case-based, evidence-based, data, failure, failed, outcomes, forum, failure forum, conventional, therapies, therapy, immunotherapy, candidate, advanced, role, new, emerging, agent, agents, immune, response Free CE CME |
|